FLT3 and acute myeloid leukemia: The problem of bioavailability has been highlighted by a randomized Phase III trial of induction chemotherapy combined with lestaurtinib in relapsed AML with FLT3-ITD, where there was no improvement in survival over chemotherapy alone.